was consistent with sinus tachycardia and echocardiography showed left ventricular dilatation with ejection fraction 30%. Viral hepatitis markers were negative. Abdominal ultrasonography was normal. Audiometric tests showed bilateral sensorineural hearing loss. We recommended diabetic diet, metformin 1000mg/day, digoxin 0.5mg/day, perindopril 5mg/day and furosemide 40mg/day. At present the patient is normoglycemic and the clinical course of cardiomyopathy resolved progressively, with ejection fraction 40%, with the treatment.

In this report, we draw attention to a very rare syndrome, Alström syndrome, which may be complicated with dilated cardiomyopathy occurred in 60 % of patients in a 182 patient series (1). It appears in infancy as an early sign of the disease or in adult age as a late appearing complication (3). In a study severe fibrosis in multiple organs has been shown in patients with AS and myocardial fibrosis ranging from moderate to severe is found in pathological investigations (1). Even if electrocardiogram results are normal, cardiac function should be evaluated to severe is found in pathological investigations (1). Even if electrocardiogram results are normal, cardiac function should be evaluated carefully by echocardiography. The chances of survival are correlated with the severity of renal and cardiac failure which are the most common causes of death in this syndrome (4). Therefore, we should keep in mind AS in differential diagnosis of a patient with infancy and early onset dilated cardiomyopathy. Early diagnosis and appropriate monitoring for complications may lead to better survival of the affected individuals.

Cihan Ünlü, İhsan Üstün1, Fahrettin Akay, Umuttan Doğan* From Departments of Ophthalmology and *Cardiology, Diyarbakır Military Hospital, Diyarbakır, 1Department of Endocrinology, GATA Haydarpaşa Military Hospital, Kadıköy/İstanbul, Turkey

References


Address for Correspondence/Yazma Adresi: Dr. İhsan Üstün Mersin Devlet Hastanesi, Endokrinoloji Poliklinikı, Mersin, Turkey Phone: +90 324 336 39 50 Mobile: +90 505 228 26 73 Fax: +90 324 336 02 56 E-mail: iustun@yahoo.com

The use of renal stents in percutaneous treatment of very large coronary arteries

Çok geniş çaplı koroner arter darlıklarında renal stent kullanımı

In current, absence of the large size coronary stents poses significant challenges to the operator. Both early and late outcomes after drug-eluting stents (DES) implantation are limited only by the available caliber of the DES (3.5 mm in the United States) and the mechanical limitations placed on current DES overexpansion (4.75 mm for Cypher, 4.25 mm for Taxus). This is also validated for bare metal stents (BMS) (3.5 to 5.0mm) and is validated for bare metal stents (BMS) (3.5 to 5.0mm) and so, there is a significant need for a large size stent that addresses this clinical challenge. We considered that the renal “vascular” stents, which have larger size, might be use in percutaneous treatment of coronary lesions in large-size vessels.

Case 1 was a 65-year-old male with a history of severe chronic obstructive pulmonary disease who was transferred to our institution for coronary angiography, which revealed the significant ostial left main coronary artery lesion and proximal left anterior descending artery stenosis (Fig. 1A). Because he represented a poor operative risk due to severe pulmonary disease, it was decided to perform percutaneous cardiac intervention. Therefore, the left main artery was stented with 5.5 x12mm renal stent with postdilatation (Fig. 1B-C) and proximal left anterior descending artery was stented with 4.0x11mm bare-metal stent (Fig. 1D-E). Final angiographic appearance was normal with TIMI 3 flow (Fig. 1E). The patient was angina free at 3 months follow-up.

Case 2 was a 61 years old male patient with stable angina pectoris was referred to coronary angiography, which demonstrated significant middle left circumflex coronary artery stenosis (Fig. 2A-D). The other coronary arteries had mild atherosclerosis only. Percutaneous transluminal coronary angioplasty, with implantation of one 8.0x12mm renal stent, was successfully performed (Fig. 2E-F). The patient did well, without symptoms over the following three months.

Whereas larger stents induce more trauma to vessels and therefore more intimal hyperplasia, more edge dissections and more coronary ruptures; underexpanded stents increase both the risk of restenosis and the likelihood of stent thrombosis. Therefore, stent size must be carefully matched with reference vessel diameter, generally aiming for a 1:1.1 balloon to artery ratio. Since standard coronary angioplasty balloons or stents have generally not been available in diameters exceeding 5 mm, placing coronary stents may still remain challenging when vessels are extremely large. Consequently, angioplasty of larger arteries and grafts is commonly performed with undersized balloons or stents. The observational data support the use of adjunctive balloon postdilatation following stent deployment in the great majority of patients

Figure 1. Angiographic images of percutaneous treatment of ostial LMCA lesion with renal stent and of proximal LAD stenosis with coronary bare metal stent

LAD- left anterior descending artery, LMCA- left main coronary artery, Cx- circumflex artery

Figure 2. Angiographic images of percutaneous cardiac intervention of Cx lesion with renal stent

LAD- left anterior descending artery, Cx- circumflex artery
(1-2). However, acute recoil after adequate expansion may occur either when the properties of the stent are altered (e.g., overexpansion) or when important compressive forces are developed by a hard and calcified plaque as is commonly seen in ostial lesions. In past, Palmaz “biliary” non-vascular stents with greater radial compressive strength and more variable sizing (diameter and length) features were also used for this purpose (3, 4). The increased strut thickness of the renal stents confers greater radial compressive strength in exchange for decreased stent flexibility. Despite the no availability of follow-up data, these stents may be use percutaneous treatment of coronary lesions in very large-size vessels until technologic development of large size-specific coronary stent.

Özcan Özke, Deniz Kumbasar1, Erdoğan İlky
Department of Cardiology, MESA Hospital, Ankara
1Department of Cardiology, Faculty of Medicine, Ankara University, Ankara, Turkey

References


Address for Correspondence/Yazışma Adresi: Dr. Özcan Özke
MESA Hastanesi, Kardioloji Bölümü, Ankara, Türkiye
Phone: +90 0 505 383 67 73 Fax: +90 312 292 99 10 E-mail: ozcanozeke@gmail.com